• ERAD-Hijacking ERADECs: Targeted Degradation of TM Proteins

  2026-06-10

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that selectively hijacks ER-associated degradation (ERAD) to eliminate transmembrane proteins. This advance addresses a fundamental challenge in targeted protein degradation and enables new research and therapeutic strategies for membrane-bound targets.

• PML Regulates HIF1AN Ubiquitination to Enhance BMSC Osteogen

  2026-06-10

  This study elucidates how promyelocytic leukemia protein (PML) enhances osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) by promoting HIF1AN ubiquitination and modulating the PI3K/AKT pathway. The findings highlight the regulatory axis of PML-HIF1AN-HIF1α-SOD3 and offer mechanistic insight relevant for osteoporosis research and regenerative medicine.

• CBD Modulates Orofacial Inflammatory Pain via Endocannabinoi

  2026-06-09

  This study demonstrates that cannabidiol (CBD) exerts potent, multi-level effects in reducing orofacial inflammatory pain and associated affective disturbances in mouse models. Mechanistic insights reveal distinct peripheral and central endocannabinoid signaling involvement, positioning CBD as a promising candidate for comprehensive pain management strategies.

• EPZ5676 and the New Era of DOT1L Inhibitors in Leukemia Rese

  2026-06-09

  Explore how EPZ5676, a highly selective DOT1L inhibitor, is redefining the translational research landscape in MLL-rearranged leukemia and epigenetic therapy. This thought-leadership article provides a mechanistic deep dive, addresses current experimental challenges, and delivers strategic guidance for researchers aiming to harness precision histone methyltransferase inhibition in acute leukemia models.

• Caspofungin and the Future of Antifungal Translational Resea

  2026-06-08

  This thought-leadership article blends mechanistic insight and strategic guidance for translational researchers investigating Candida infections. It explores how Caspofungin, a lipopeptide antifungal drug, enables cutting-edge research on β-(1,3)-D-glucan biosynthesis inhibition, contextualized within evolving resistance patterns and new antifungal benchmarks. Evidence from recent comparative efficacy studies, including those on ibrexafungerp, frames the clinical and experimental landscape. Protocol parameters and strategic considerations are provided to empower reproducible, high-impact antifungal therapeutics research.

• Network Medicine Identifies Apigenin as a Neuroprotective Fl

  2026-06-08

  A recent network medicine study systematically identified flavonoids with therapeutic potential against Alzheimer’s disease, highlighting Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) for its ability to modulate apoptosis and neuroinflammation. The findings offer actionable insights into flavonoid-based neuroprotection and guide experimental design for cellular and in vivo models.

• Protein A/G Magnetic Co-IP/IP Kit: Mechanism, Evidence & Lim

  2026-06-07

  The Protein A/G Magnetic Co-IP/IP Kit leverages recombinant Protein A/G magnetic beads for high-specificity co-immunoprecipitation and antibody purification. Its design supports reproducible protein-protein interaction analysis while minimizing protein degradation, validated by peer-reviewed and product documentation.

• G418 Sulfate: Precision Selection and Antiviral Innovation

  2026-06-06

  Geneticin, G-418 Sulfate is the gold-standard selective agent for robust genetic engineering and advanced antiviral workflows. With high purity and cross-domain efficacy, APExBIO’s ultra-pure G418 delivers reproducible results for stable cell line generation and targeted Dengue virus inhibition.

• Anlotinib Hydrochloride: Multi-Target Inhibition of Tumor An

  2026-06-05

  This study provides mechanistic and comparative evidence that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly suppresses tumor angiogenesis by inhibiting VEGFR2, PDGFRβ, and FGFR1 activation. Its superior efficacy over established TKIs positions it as a valuable tool for experimental cancer research targeting endothelial migration and neovascularization.

• Substance P in Applied Pain and Inflammation Models

  2026-06-05

  Unlock precise pain transmission and inflammation research with high-purity Substance P from APExBIO. This article delivers actionable protocols, advanced troubleshooting, and data-driven insights for maximizing reproducibility and sensitivity in neurokinin signaling assays.

• GCG Disrupts SARS-CoV-2 Nucleocapsid LLPS: Mechanistic Insig

  2026-06-04

  Zhao et al. revealed that the SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process crucial for viral replication. Their study identifies (-)-gallocatechin gallate (GCG) as a disruptor of this phase separation, highlighting a new mechanistic target for antiviral strategies and providing a foundation for probe-based research into viral assembly.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-04

  Harness the precision of Anlotinib hydrochloride for robust, reproducible endothelial and cancer cell assays. This guide delivers actionable protocols, comparative insights, and troubleshooting strategies to maximize anti-angiogenic research outcomes.

• Golgi-Tracker Green: Driving Translational Golgi Research Fo

  2026-06-03

  Explore how Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe, advances live-cell Golgi apparatus imaging and mechanistic studies of sphingolipid metabolism. This article synthesizes recent oncology findings, compares competing technologies, and delivers actionable guidance for translational researchers seeking to optimize organelle-targeting strategies for next-generation biomedical discovery.

• Doxorubicin HCl: Mechanisms, Models, and Translational Impac

  2026-06-03

  This thought-leadership article explores the multidimensional role of Doxorubicin (Adriamycin) HCl in cancer chemotherapy research, focusing on mechanistic insights, experimental rigor, and strategic guidance for translational scientists. Integrating recent advances in nucleolar architecture and DNA topoisomerase II inhibition, we provide actionable protocols, highlight the competitive landscape, and offer a forward-looking perspective on biomarker-driven oncology and cardiotoxicity modeling. APExBIO’s Doxorubicin HCl (SKU A1832) is profiled as a best-in-class tool for high-fidelity, reproducible results.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Protein

  2026-06-02

  Cy3 NHS ester (non-sulfonated) addresses the need for precise, high-sensitivity labeling of proteins, peptides, and oligonucleotides where direct water solubility is not required. It is ideal for workflows requiring robust orange fluorescence compatible with standard TRITC filter sets. However, its requirement for organic co-solvents limits use with highly sensitive or unstable biomolecules.

16308 records 1/1088 page Next 12345 下5页 Last page